Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive Treatment
Key facts
- Who runs it
- University Hospital, Brest
- Where
- France5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Starts
- 1 Feb 2027
- Expected to end
- 1 Aug 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Anakinra
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
- Stable cytoreductive therapy for at least 6 months
- Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
- Adult patient capable of providing informed consent
Who cannot take part
- Concomitant immunosuppressive therapy
- Recurrent or poorly controlled infections
- Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
- Thrombocytopenia < 100 G/L
- Neutropenia < 1 G/L
- Refusal to participate
- Patient under legal protection (guardianship, curatorship, etc.)
- Patients unable to consent
- Positive urine pregnancy test at screening / pregnant or breastfeeding women
- Lack of understanding of questionnaires or inability to follow up
- Women of childbearing potential unwilling to use a highly effective contraceptive methods
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Myeloproliferative neoplasm
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Myeloproliferative neoplasms (MPNs) - polycythemia vera, essential thrombocythemia, and primary myelofibrosis - are characterized by excessive myeloid proliferation driven by mutations affecting the JAK2, CALR, and MPL genes, resulting in constitutive activation of hematopoietic cytokine signaling pathways. These hematological malignancies carry an increased risk of thrombosis and may evolve toward secondary myelofibrosis or acute leukemia. Bone marrow inflammation, particularly through interleukin-1 (IL-1), plays a major role in clonal expansion and the clinical expression of these diseases, as demonstrated by preclinical models showing the beneficial effect of its inhibition.
Read full original descriptionShow less
Anakinra, an IL-1 receptor antagonist widely used in rheumatology but never evaluated in MPNs, represents a promising therapeutic option. This proof-of-concept study will randomize 50 patients with a suboptimal response to cytoreductive therapy into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or cytoreductive therapy alone (n=25). The primary endpoint will be the reduction in serum calprotectin levels, a key inflammatory marker of the IL-1 loop that has recently demonstrated prognostic relevance in MPNs. Secondary endpoints will include improvements in hematological parameters, driver mutation allelic burden, pro-inflammatory cytokines, and quality of life.
This study represents an essential step toward larger trials aimed at demonstrating a durable reduction in thrombotic risk and disease progression.
The 2 groups in the trial
- Anakinra + cytoreductive therapyTreatment being tested
Anakinra 100 mg/day subcutaneously for 3 months, added to ongoing standard cytoreductive therapy (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. Additional Month 1 safety/tolerability visit (clinical exam, routine biology, AE/SAE and injection-site reaction review, compliance check) and an injection diary for adherence.
Treatment: Anakinra
- Cytoreductive therapy aloneNo study treatment, for comparison
Standard cytoreductive therapy continued alone, with no additional study treatment (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. No Month 1 visit.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from NCT07946289, who can take part
- Record updated
- 18 November 2026